Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
J Dermatolog TreatJun 23, 2026 (epub)
Clinical ResearchDermatology
Jingjing Liu, Junyi Shao, Liyue Hou et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of a phase III trial evaluated the efficacy of vunakizumab in 690 patients with moderate-to-severe plaque psoriasis. The study found that significantly more patients receiving vunakizumab achieved PASI 75, PASI 90, and PASI 100 responses at week 12 compared to those on placebo, regardless of baseline disease features.
Key findings
- At week 12, 75% of patients on vunakizumab achieved PASI 75 compared to placebo.
- Vunakizumab showed higher response rates at weeks 4, 8, and 12 across various disease features.
- At week 52, treatment responses were similar between continuous vunakizumab users and those switched from placebo.
Why it matters
Understanding the efficacy of treatments like vunakizumab across different patient characteristics can help clinicians make informed decisions about managing moderate-to-severe plaque psoriasis, potentially improving patient outcomes.